These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 5104098)

  • 1. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 2. Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa.
    Bertler A; Jeppsson PG; Nordgren L; Rosengren E
    Acta Neurol Scand; 1971; 47(4):393-402. PubMed ID: 4941731
    [No Abstract]   [Full Text] [Related]  

  • 3. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 5. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 6. Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.
    Tohgi H; Abe T; Takahashi S; Nozaki Y; Kikuchi T
    Neurosci Lett; 1991 Jun; 127(2):212-4. PubMed ID: 1908962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 8. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J; Sharpe D; Curzon G
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract]   [Full Text] [Related]  

  • 9. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa and dopamine in cerebrospinal fluid.
    Papavasiliou PS; Cotzias GC; Lawrence WH
    Neurology; 1973 Jul; 23(7):756-9. PubMed ID: 4736493
    [No Abstract]   [Full Text] [Related]  

  • 11. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
    Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
    J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
    [No Abstract]   [Full Text] [Related]  

  • 13. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
    Hare TA; Beasley BL; Chambers RA; Boehme DH; Vogel WH
    Clin Chim Acta; 1973 May; 45(3):273-80. PubMed ID: 4708057
    [No Abstract]   [Full Text] [Related]  

  • 14. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 15. L-Dopa treatment in Parkinson's Disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
    [No Abstract]   [Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa.
    Wilk S; Mones R
    J Neurochem; 1971 Sep; 18(9):1771-3. PubMed ID: 5571114
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
    Tohgi H; Abe T; Takahashi S
    J Neural Transm Park Dis Dement Sect; 1993; 5(1):27-34. PubMed ID: 8439390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.
    Fekete M; Tárczy M; Bihari K; Katona G
    Psychopharmacology (Berl); 1984; 82(1-2):93-4. PubMed ID: 6420835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biochemistry of catecholamines in relation to Parkinson's disease.
    Hinterberger H
    Aust N Z J Med; 1971 May; 1():Suppl 1:14-8. PubMed ID: 5292808
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.